Systemic barriers hinder psychedelic therapy's clinical progress despite promising early results
Original framing: “Mind-altering substances are (still) falling short in clinical trials” — MIT Technology Review
The article foregrounds scientific concerns such as trial design flaws, regulatory hurdles, and the unique pharmacodynamics of psychedelics, providing concrete examples and citations. This constitutes its strongest dimension.
The article foregrounds scientific rigor but underrepresents Indigenous, historical, and artistic dimensions that are essential for a truly systemic understanding of psychedelic therapy.
By weaving together cultural wisdom, regulatory innovation, and equitable funding, we can move beyond hype and address the structural barriers that currently stall progress. A trickster lens reveals the paradox of market‑driven optimism colliding with entrenched bureaucratic inertia, urging a more humble, pluralistic approach. Integrating these diverse perspectives creates a resilient framework capable of guiding both present trials and future policy landscapes.